Research at Cain
FDA approves everolimus for tuberous sclerosis-associated seizures, a treatment first discovered at Texas Children's Hospital
On April 10, 2018, the Food and Drug Administration (FDA) approved everolimus tablets for oral suspension (brand name: Afinitor Dispersz, Novartis Pharmaceuticals Corporation) as an adjunctive therapy to treat partial-onset refractory seizures in adults and children over 2 years of age with Tuberous Sclerosis Complex (TSC). Tuberous Sclerois isa genetic disorder that affects one million people worldwide and is characterized by benign tumors in several organs, epilepsy, behavioral problems and intellectual disability.
A study shows that structural alterations in neurons and the resulting memory deficits that arise after a single generalized seizure can be reversed by inhibiting the Phosphoinositide 3-kinase/Akt kinase/mechanistic target of rapamycin (i.e. PI3K/Akt/mTOR) signaling pathway.